Literature DB >> 2064103

Snake venom coagulopathy: use and abuse of blood products in the treatment of pit viper envenomation.

J L Burgess1, R C Dart.   

Abstract

Coagulopathies are commonly encountered in victims of pit viper envenomation. In the majority of patients these defects improve with administration of antivenin. However, blood products are often transfused based on arbitrary criteria and with significant risk to the patient. This article documents the effectiveness and risks of antivenin administration and the risks of blood product transfusion. We recommend that blood products not be used except for clearly defined clinical indications.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2064103     DOI: 10.1016/s0196-0644(05)80845-5

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  5 in total

Review 1.  Antivenom therapy in the Americas.

Authors:  K Heard; G F O'Malley; R C Dart
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

2.  Severe coagulopathy after a massasauga rattlesnake bite.

Authors:  Marissa Laureano; Mark Crowther
Journal:  CMAJ       Date:  2018-02-20       Impact factor: 8.262

3.  An antivenin resistant, IVIg-corticosteroids responsive viper induced thrombocytopenia.

Authors:  Matteo Turetta; Fabio Del Ben; Donatella Londero; Agostino Steffan; Pierpaolo Pillinini
Journal:  Toxicol Rep       Date:  2022-03-29

Review 4.  Snakebite management in Iran: Devising a protocol.

Authors:  Seyed Mostafa Monzavi; Bita Dadpour; Reza Afshari
Journal:  J Res Med Sci       Date:  2014-02       Impact factor: 1.852

Review 5.  Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.

Authors:  Rashmi Dixit; Jenny Herz; Richard Dalton; Robert Booy
Journal:  Vaccine       Date:  2016-01-20       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.